Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables

Abstract

Assessing patient eligibility for hematopoietic stem cell transplantation (HSCT) remains a complex, multifaceted challenge. Among these challenges, the paucity of comprehensive clinical data to guide decision making remains problematic coupled with unclear trade-offs between patient, disease and local HSCT center factors. Moreover, it is unclear that the modification of poor patient characteristics will improve post-HSCT outcomes. However, the use of Comorbidity Indices and Comprehensive Geriatric Assessments helps meet this challenge, but may be limited by overlapping patient characteristics. The increasing consideration for pre-HSCT psychosocial assessments and interventions remains to be studied. Ultimately, the decision to proceed with a HSCT remains interdisciplinary while considering the available evidence discussed in this review.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:1259–68. https://doi.org/10.1038/bmt.2010.94

    Article  CAS  PubMed  Google Scholar 

  2. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–9. https://doi.org/10.1200/JCO.2006.09.0100

    Article  PubMed  Google Scholar 

  3. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–7.

    Article  CAS  PubMed  Google Scholar 

  4. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54.

    CAS  PubMed  Google Scholar 

  5. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83:614–7. https://doi.org/10.1002/ajh.21191

    Article  PubMed  Google Scholar 

  6. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20:1796–803. https://doi.org/10.1016/j.bbmt.2014.07.013

    Article  PubMed  PubMed Central  Google Scholar 

  7. Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433–5. https://doi.org/10.1002/ajh.23108

    Article  PubMed  Google Scholar 

  8. Martin N, Borchiellini D, Coso D, Gastaud L, Boscagli A, Saudes L, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma. 2015;56:2379–87. https://doi.org/10.3109/10428194.2014.1001987

    Article  CAS  PubMed  Google Scholar 

  9. Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684–9. https://doi.org/10.1016/j.bbmt.2014.01.025

    Article  CAS  PubMed  Google Scholar 

  10. D’Souza A, Zhu X. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides, 2016. https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx

  11. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405–11. https://doi.org/10.1200/JCO.2009.21.8073

    Article  PubMed  Google Scholar 

  12. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–87. https://doi.org/10.1200/JCO.2009.25.4821

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874–83. https://doi.org/10.1001/jama.2011.1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2010;16:509–14. https://doi.org/10.1016/j.bbmt.2009.11.017

    Article  CAS  PubMed  Google Scholar 

  15. Rosko A, Artz A. Aging: treating the older patient. Biol Blood Marrow Transplant. 2017;23:193–200. https://doi.org/10.1016/j.bbmt.2016.11.007

    Article  PubMed  Google Scholar 

  16. Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013;19:429–34. https://doi.org/10.1016/j.bbmt.2012.11.006

    Article  PubMed  Google Scholar 

  17. Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014;5:422–30. https://doi.org/10.1016/j.jgo.2014.04.004

    Article  PubMed  PubMed Central  Google Scholar 

  18. Melzer D, Frayling TM, Murray A, Hurst AJ, Harries LW, Song H, et al. A common variant of thep16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev. 2007;128:370–7. https://doi.org/10.1016/j.mad.2007.03.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Liu Y,Sanoff HK,Cho H,Burd CE,Torrice C,Ibrahim JG, et al. Expression ofp16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8:439–48.

    Article  CAS  PubMed  Google Scholar 

  20. Lagro J, Studenski SA, Olde Rikkert MG. Predicting chemotherapy toxicity in older adults and the importance of geriatric assessment. J Clin Oncol. 2012;30:560 https://doi.org/10.1200/JCO.2011.39.4858. author reply 561-562

    Article  PubMed  Google Scholar 

  21. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38:275–83. https://doi.org/10.1016/j.leukres.2013.12.018

    Article  CAS  PubMed  Google Scholar 

  22. Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12:82–126.

    Article  PubMed  Google Scholar 

  23. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373–9. https://doi.org/10.3324/haematol.2014.103655

    Article  PubMed  PubMed Central  Google Scholar 

  24. Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018;53:565–75. https://doi.org/10.1038/s41409-017-0021-4

    Article  CAS  PubMed  Google Scholar 

  25. Hegde A, Murthy HS. Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? Bone Marrow Transplant. 2018;53:3–10. https://doi.org/10.1038/bmt.2017.192

    Article  CAS  PubMed  Google Scholar 

  26. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223–9.

    Article  CAS  PubMed  Google Scholar 

  27. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1261–9. https://doi.org/10.1016/j.bbmt.2006.07.016

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant. 2009;15:447–53. https://doi.org/10.1016/j.bbmt.2008.12.509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006;144:407–14.

    Article  PubMed  Google Scholar 

  30. El-Khatib M, Bou-Khalil P, Abbas O, Salman A, Jamaleddine G. Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation. Lung. 2007;185:321–4. https://doi.org/10.1007/s00408-007-9047-5

    Article  PubMed  Google Scholar 

  31. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1072–8. https://doi.org/10.1016/j.bbmt.2010.11.018

    Article  PubMed  Google Scholar 

  32. Coghlan JG, Handler CE, Kottaridis PD. Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2007;20:247–63. https://doi.org/10.1016/j.beha.2006.09.005

    Article  CAS  PubMed  Google Scholar 

  33. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant. 2001;28:283–7. https://doi.org/10.1038/sj.bmt.1703133

    Article  CAS  PubMed  Google Scholar 

  34. Hurley P, Konety S, Cao Q, Weisdorf D, Blaes A. Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done? Biol Blood Marrow Transplant. 2015;21:300–4. https://doi.org/10.1016/j.bbmt.2014.10.011

    Article  PubMed  Google Scholar 

  35. Nakamae H, Hino M, Akahori M, Terada Y, Yamane T, Ohta K, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2004;76:1–7. https://doi.org/10.1002/ajh.20042

    Article  PubMed  Google Scholar 

  36. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.

    Article  CAS  PubMed  Google Scholar 

  37. Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20:1248–51. https://doi.org/10.1016/j.bbmt.2014.04.024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009;94:249–57. https://doi.org/10.3324/haematol.13756

    Article  PubMed  PubMed Central  Google Scholar 

  39. Colecchia A, Marasco G, Ravaioli F, Kleinschmidt K, Masetti R, Prete A, et al. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Bone Marrow Transplant. 2017;52:494–7. https://doi.org/10.1038/bmt.2016.320

    Article  CAS  PubMed  Google Scholar 

  40. Lau JE, Weber C, Earl M, Rybicki LA, Carlstrom KD, Wenzell CM, et al. Outcomes after autologous SCT in lymphoma patients grouped by weight. Bone Marrow Transplant. 2015;50:652–7. https://doi.org/10.1038/bmt.2014.327

    Article  CAS  PubMed  Google Scholar 

  41. Gleimer M, Li Y, Chang L, Paczesny S, Hanauer DA, Frame DG, et al. Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes. Bone Marrow Transplant. 2015;50:402–10. https://doi.org/10.1038/bmt.2014.280

    Article  CAS  PubMed  Google Scholar 

  42. Baumgartner A, Zueger N, Bargetzi A, Medinger M, Passweg JR, Stanga Z, et al. Association of nutritional parameters with clinical outcomes in patients with acute myeloid leukemia undergoing haematopoietic stem cell transplantation. Ann Nutr Metab. 2016;69:89–98. https://doi.org/10.1159/000449451

    Article  CAS  PubMed  Google Scholar 

  43. Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant. 2016;51:1337–41. https://doi.org/10.1038/bmt.2016.136

    Article  CAS  PubMed  Google Scholar 

  44. Ataei S, Hadjibabaie M, Moslehi A, Taghizadeh-Ghehi M, Ashouri A, Amini E, et al. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2015;33:67–74. https://doi.org/10.1002/hon.2141

    Article  CAS  PubMed  Google Scholar 

  45. Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, Yano S, et al. Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. Ann Hematol. 2013;92:255–60. https://doi.org/10.1007/s00277-012-1584-1

    Article  CAS  PubMed  Google Scholar 

  46. Shimoi T, Ando M, Munakata W, Kobayashi T, Kakihana K, Ohashi K, et al. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transplant. 2013;48:80–84. https://doi.org/10.1038/bmt.2012.85

    Article  CAS  PubMed  Google Scholar 

  47. Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:394–400. https://doi.org/10.1016/j.bbmt.2010.07.010

    Article  PubMed  Google Scholar 

  48. Melkos AB, Massenkeil G, Arnold R, Reichart PA. Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome. Clin Oral Investig. 2003;7:113–5. https://doi.org/10.1007/s00784-003-0209-4

    Article  CAS  PubMed  Google Scholar 

  49. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387–404.

    Article  CAS  PubMed  Google Scholar 

  50. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:954–64. https://doi.org/10.1016/j.bbmt.2006.05.015

    Article  PubMed  Google Scholar 

  51. Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, et al. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2015;21:848–54. https://doi.org/10.1016/j.bbmt.2015.01.011

    Article  PubMed  PubMed Central  Google Scholar 

  52. Mori Y, Teshima T, Kamezaki K, Kato K, Takenaka K, Iwasaki H, et al. Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. Bone Marrow Transplant. 2012;47:1075–81. https://doi.org/10.1038/bmt.2011.229

    Article  CAS  PubMed  Google Scholar 

  53. Kishore BW, Nikolousis D, Lovell E, Milligan R, Holder D, Bratby K, Murthy L, Paneesha V. Pre-transplantation assessment of mortality (PAM) score is a poor predictor for survival in the highest risk group when used in T cell depleted myeloablative allogeneic transplants. Blood. 2013;122:5553. http://www.bloodjournal.org/content/122/21/5553

    Google Scholar 

  54. Wiseman D, Nikolousis E, Lovell R, Milligan D, Holder K, Bratby L, et al. Pre-transplantation assessment of mortality (PAM) score is a poor predictor for survival in the highest risk group when used In T cell depleted myeloablative allogeneic transplants. Blood. 2013;122:5553–5553.

    Article  Google Scholar 

  55. Labonte L, Iqbal T, Zaidi MA, McDiarmid SA, Huebsch LB, Tay J, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:1039–44. https://doi.org/10.1016/j.bbmt.2008.06.019

    Article  PubMed  Google Scholar 

  56. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749–56. https://doi.org/10.1038/bmt.2011.110

    Article  CAS  PubMed  Google Scholar 

  57. Lozano SO,E, Iacobelli S, van Biezen A, Beelen D, Finke J, Mufti G, et al. The EBMT score predicts transplant related mortality and overall survival after allogeneic stem cell transplantation for myelodysplastic syndromes. Blood. 2015;126:3223. http://www.bloodjournal.org/content/126/23/3223

    Google Scholar 

  58. Gul Z, Khan H, Bashir Q, Shah N, Parmar S, Dinh YT, et al. EBMT risk score for pre transplant risk assessment in patients with multiple myeloma. Blood. 2012;120:3094–3094.

    Google Scholar 

  59. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.

    Article  CAS  PubMed  Google Scholar 

  60. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001. https://doi.org/10.1002/cncr.23375

    Article  PubMed  Google Scholar 

  62. Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant. 2015;50:1405–10. https://doi.org/10.1038/bmt.2015.165

    Article  CAS  PubMed  Google Scholar 

  63. Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant. 2012;47:528–34. https://doi.org/10.1038/bmt.2011.138

    Article  CAS  PubMed  Google Scholar 

  64. Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, et al. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant. 2014;20:1553–9. https://doi.org/10.1016/j.bbmt.2014.06.005

    Article  PubMed  Google Scholar 

  65. Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol. 2013;88:497–502. https://doi.org/10.1002/ajh.23443

    Article  PubMed  Google Scholar 

  66. Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, et al. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplant. 2014;49:1323–9. https://doi.org/10.1038/bmt.2014.155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Berro M,Rivas MM,Arbelbide JA,Basquiera AL,Vitriu A,Foncuberta MC, et al. HCT.CI in autologous stem cell transplantation. Predicting early and late transplant related mortality. Blood. 2016;128:3449

    Google Scholar 

  68. Kassar M, Gregory SA, Shell K, Venugopal P, Shammo J, Farhat MI, et al. Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma. J Clin Oncol. 2007;25(18_suppl):7102–7102. https://doi.org/10.1200/jco.2007.25.18_suppl.7102

    Article  Google Scholar 

  69. Michelis FV,Messner HA,Uhm J,Lambie A,McGillis L,Gupta V, et al. The modified pre-transplant EBMT risk score is superior to the HCT-CI score in predicting overall survival and non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Blood. 2013;122:2153

    Google Scholar 

  70. Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, et al. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010;95:810–8. https://doi.org/10.3324/haematol.2009.011809

    Article  PubMed  Google Scholar 

  71. Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402–8 e401. https://doi.org/10.1016/j.bbmt.2013.12.557

    Article  PubMed  Google Scholar 

  72. Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H. Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation. Am J Hematol. 2014;89:E138–141. https://doi.org/10.1002/ajh.23764

    Article  CAS  PubMed  Google Scholar 

  73. Foster LW, McLellan LJ, Rybicki LA, Dabney J, Welsh E, Bolwell BJ. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals. Bone Marrow Transplant. 2006;37:223–8. https://doi.org/10.1038/sj.bmt.1705219

    Article  CAS  PubMed  Google Scholar 

  74. Foster LW, McLellan L, Rybicki L, Tyler T, Bolwell BJ. Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria. Bone Marrow Transplant. 2009;44:607–12. https://doi.org/10.1038/bmt.2009.58

    Article  CAS  PubMed  Google Scholar 

  75. Bevans M, Wehrlen L, Prachenko O, Soeken K, Zabora J, Wallen GR. Distress screening in allogeneic hematopoietic stem cell (HSCT) caregivers and patients. Psychooncology. 2011;20:615–22. https://doi.org/10.1002/pon.1906

    Article  PubMed  PubMed Central  Google Scholar 

  76. Bultz BD, Groff SL, Fitch M, Blais MC, Howes J, Levy K, et al. Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice. Psychooncology. 2011;20:463–9. https://doi.org/10.1002/pon.1932

    Article  PubMed  Google Scholar 

  77. Giese-Davis J, Waller A, Carlson LE, Groff S, Zhong L, Neri E, et al. Screening for distress, the 6th vital sign: common problems in cancer outpatients over one year in usual care: associations with marital status, sex, and age. BMC Cancer. 2012;12:441 https://doi.org/10.1186/1471-2407-12-441

    Article  PubMed  PubMed Central  Google Scholar 

  78. Garcia C Jr, Botega NJ, De Souza CA. A psychosocial assessment interview of candidates for hematopoietic stem cell transplantation. Haematologica. 2005;90:570–2.

    PubMed  Google Scholar 

  79. Foster LW, McLellan L, Rybicki L, Dabney J, Visnosky M, Bolwell B. Utility of the psychosocial assessment of candidates for transplantation (PACT) scale in allogeneic BMT. Bone Marrow Transplant. 2009;44:375–80. https://doi.org/10.1038/bmt.2009.37

    Article  CAS  PubMed  Google Scholar 

  80. Olbrisch MEL, J L, Hamer R. ThePACT: a rating scale for the study of clinical decision-making in psychosocial screening of organ transplant candidates. Clin Transplant. 1989;3:164–9.

    Google Scholar 

  81. Hong S, Rybicki L, Abounader D, Dabney J, Dean RM, Gerds AT, et al. Pre-transplant psychosocial assessment and outcomes of allogeneic hematopoietic cell transplantation in adults. Blood. 2016;128:3552–3552.

    Google Scholar 

  82. Hoodin F, Zhao L, Carey J, Levine JE, Kitko C. Impact of psychological screening on routine outpatient care of hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2013;19:1493–7. https://doi.org/10.1016/j.bbmt.2013.07.019

    Article  PubMed  PubMed Central  Google Scholar 

  83. Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, et al. Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Psychooncology. 2016;26:1164–71. https://doi.org/10.1002/pon.4295

    Article  PubMed  Google Scholar 

  84. Ehrlich KB, Miller GE, Scheide T, Baveja S, Weiland R, Galvin J, et al. Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:1594–8. https://doi.org/10.1038/bmt.2016.191

    Article  CAS  PubMed  Google Scholar 

  85. Baliousis M, Rennoldson M, Snowden JA. Psychological interventions for distress in adults undergoing haematopoietic stem cell transplantation: a systematic review with meta-analysis. Psychooncology. 2016;25:400–11. https://doi.org/10.1002/pon.3925

    Article  PubMed  Google Scholar 

  86. Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, et al. Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. Bone Marrow Transplant. 2017;52:1651–7. https://doi.org/10.1038/bmt.2017.190

    Article  CAS  PubMed  Google Scholar 

  87. El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, et al. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017;123:1828–38. https://doi.org/10.1002/cncr.30546

    Article  PubMed  Google Scholar 

  88. Haynes RT, D W, Sackett DL. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 1–2.

    Google Scholar 

  89. Bishop MM, Rodrigue JR, Wingard JR. Mismanaging the gift of life: noncompliance in the context of adult stem cell transplantation. Bone Marrow Transplant. 2002;29:875–80. https://doi.org/10.1038/sj.bmt.1703523

    Article  CAS  PubMed  Google Scholar 

  90. Mumby PB, Hurley C, Samsi M, Thilges S, Parthasarathy M, Stiff PJ. Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants. Bone Marrow Transplant. 2012;47:556–61. https://doi.org/10.1038/bmt.2011.129

    Article  CAS  PubMed  Google Scholar 

  91. Rodrigue JR, Pearman TP, Moreb J. Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. Int J Behav Med. 1999;6:241–54. https://doi.org/10.1207/s15327558ijbm0603_3

    Article  CAS  PubMed  Google Scholar 

  92. Stagno S, Busby K, Shapiro A, Kotz M. Patients at risk: addressing addiction in patients undergoing hematopoietic SCT. Bone Marrow Transplant. 2008;42:221–6. https://doi.org/10.1038/bmt.2008.211

    Article  PubMed  Google Scholar 

  93. Chang G, Antin JH, Orav EJ, Randall U, McGarigle C, Behr HM. Substance abuse and bone marrow transplant. Am J Drug Alcohol Abus. 1997;23:301–8.

    Article  CAS  Google Scholar 

  94. Chang G, Orav EJ, Tong MY, Antin JH. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004;45:378–85. https://doi.org/10.1176/appi.psy.45.5.378

    Article  PubMed  Google Scholar 

  95. Turcotte LM, Verneris MR. Is it better to be rich or relaxed? Sociobiology meets bone marrow transplant. Clin Cancer Res. 2016;22:6–8. https://doi.org/10.1158/1078-0432.CCR-15-2112

    Article  PubMed  Google Scholar 

  96. Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, et al. Patient-reported outcomes and socioeconomic status as predictors of clinical outcomes after hematopoietic stem cell transplantation: a study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant. 2016;22:2256–63. https://doi.org/10.1016/j.bbmt.2016.08.016

    Article  PubMed  PubMed Central  Google Scholar 

  97. Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, et al. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50:1326–30. https://doi.org/10.1038/bmt.2015.166

    Article  CAS  PubMed  Google Scholar 

  98. Silla L, Fischer GB, Paz A, Daudt LE, Mitto I, Katz B, et al. Patient socioeconomic status as a prognostic factor for allo-SCT. Bone Marrow Transplant. 2009;43:571–7. https://doi.org/10.1038/bmt.2008.358

    Article  CAS  PubMed  Google Scholar 

  99. Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, et al. Association of socioeconomic status with outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2016;22:1141–4. https://doi.org/10.1016/j.bbmt.2016.03.011

    Article  PubMed  Google Scholar 

  100. Frick E, Motzke C, Fischer N, Busch R, Bumeder I. Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology. 2005;14:759–70. https://doi.org/10.1002/pon.908

    Article  CAS  PubMed  Google Scholar 

  101. Beattie S, Lebel S, Petricone-Westwood D, Wilson KG, Harris C, Devins G, et al. Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation. Psychooncology. 2016;26:2224–31. https://doi.org/10.1002/pon.4340

    Article  Google Scholar 

  102. Beattie S, Lebel S, Tay J. The influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literature. PLoS ONE. 2013;8:e61586 https://doi.org/10.1371/journal.pone.0061586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90. https://doi.org/10.1038/nrclinonc.2012.150

    Article  CAS  PubMed  Google Scholar 

  104. Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making--emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:125–37. https://doi.org/10.1016/j.jval.2015.12.016

    Article  PubMed  Google Scholar 

  105. Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making--an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:1–13. https://doi.org/10.1016/j.jval.2015.12.003

    Article  PubMed  Google Scholar 

  106. Guler S, Hurton S, Cwinn M, Molinari M. Levels in decision making and techniques for clinicians. Glob J Dig Dis. 2015;1:1–11. https://doi.org/10.4172/2472-1891.100002

    Article  Google Scholar 

  107. Norris S, Shendale S. Decision-making for guideline development at WHO. In: WHO handbook for guideline development, 2nd ed. World Health Organization; 2014, p. 201-14. http://www.who.int/publications/guidelines/Chp16_May2016.pdf, http://www.who.int/publications/guidelines/handbook_2nd_ed.pdf

  108. Institute OHR. Patient Decision Aids. 2015. https://decisionaid.ohri.ca/

  109. Drug and Therapeutics Bulletin. An introduction to patient decision aids. BMJ. 2013;347:f4147 https://doi.org/10.1136/bmj.f4147

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Tay.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tay, J., Daly, A., Jamani, K. et al. Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. Bone Marrow Transplant 54, 368–382 (2019). https://doi.org/10.1038/s41409-018-0265-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0265-7

This article is cited by

Search

Quick links